Effect of exposure to selective serotonin reuptake inhibitors. In Utero on fetal growth: Potential role for the IGF-I and HPA axes

Pediatric Research

Volumn 65, Issue 2, 2009, Pages 236-241

  Davidson, Shmuel ^a   Prokonov, Diana ^a   Taler, Michal ^b   Maayan, Rachel ^b   Harell, Daniella ^a   Gil Ad, Irit ^b   Weizman, Abraham ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CITALOPRAM; HYDROCORTISONE; PAROXETINE; PRASTERONE; PRASTERONE SULFATE; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BEHAVIOR DISORDER; BODY HEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROWN HEEL LENGTH; DRUG EFFECT; DRUG URINE LEVEL; FEMALE; FETUS GROWTH; HEAD CIRCUMFERENCE; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; MALE; NEWBORN; PATHOPHYSIOLOGY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SCORING SYSTEM; SMALL FOR DATE INFANT; THYROTROPIN BLOOD LEVEL; UMBILICAL CORD BLOOD;

ADULT; BIRTH WEIGHT; CASE-CONTROL STUDIES; CITALOPRAM; FEMALE; FETAL BLOOD; FETAL DEVELOPMENT; FETAL GROWTH RETARDATION; FETUS; FLUOXETINE; HORMONES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; MALE; PAROXETINE; PITUITARY-ADRENAL SYSTEM; PLACENTA; PREGNANCY; SEROTONIN UPTAKE INHIBITORS;

EID: 60449107170     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e318193594a     Document Type: Article

References (43)

1. Laine K, Heikkinen T, Ekblad U, Kero P 2003 Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 60:720-726
2. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Tiggs W 2004 Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65:230-237
3. Hampton T 2006 Antidepressants and pregnancy. Weighing risks and benefits - no easy task. JAMA 295:1631-1633
4. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matusui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G 1998 Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 279:609-610
5. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G 2005 Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 193:2004-2009
6. Einarson TR, Einarson A 2005 Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 14:823-827
7. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA 2007 First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675-2683
8. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM; National Birth Defects Prevention Study 2007 Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684-2692
9. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Bérard A, Koren G 2007 Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 29:918-926
10. Costei AM, Kozer E, Ho T, Ito S, Koren G 2002 Perinatal outcome following third trimester exposure, to paroxetine. Arch Pediatr Adolesc Med 156:1129-1132
11. Nordeng H, Lindemann R, Perminov KV, Reikvam A 2001 Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 90:288-291
12. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Winser KL 2005 Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293:2372-2383
13. Sanz EJ, De-Las-Cuevas C, Kiuru A, Bate A, Edwards R 2005 Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365:482-487
14. Ferreira E, Carceller AM, Agogue C, Martin BZ, St-Andre M, Francoeur D, Berard A 2007 Effect of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 119:52-59
15. Lattimore KA, Don SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM 2005 Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatal 25:595-604
16. Chambers CD, Hernandez-Diaz S, Van Marter L, Werter MM, Louik C, Jones KL, Mitchell AA 2006 Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579-587
17. Anderson OM, Czarkowski K, Ravski N, Epperson CN 2004 Platelet serotonin in newboms and infants: ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors. Pediatr Res 56:418-422
18. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C 2006 Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63:898-906
19. Simon GE, Cunningham ML, Davis RL 2002 Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159:2055-2061
20. Kallen B 2004 Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 158:312-316
21. Malm H, Klaukka T, Neuvonen PJ 2005 Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106:1289-1296
22. Weintrob N, Cohen D, Klipper-Aurbach Y, Zadik Z, Dickerman Z 2002 Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156:696-701
23. Davidson S, Shtaif B, Gil-Ad I, Maayan R, Sulkes J, Weizman A, Merlob P 2001 Insulin, insulin-like growth factors-I and -II and insulin-like growth factor binding protein-3 in newborn serum: association with normal fetal head growth and head circumference. J Pediatr Endocrinol Metab 14:151-158
24. Davidson S, Hod M, Merlob P, Shtaif B 2006 Leptin, insulin, insulin-like growth factors and their binding proteins in cord serum: insight into fetal growth and discordancy. Clin Endocrinol (Oxf) 65:586-592
25. Delarue C, Contesse V, Lenglet S, Sicard F, Perraudin V, Leffebvre H, Kodjo M, Leboulenger F, Yon L, Gallo-Payer N, Vaudry H 2001 Role of neurotransmitters and neuropeptides in the regulation of the adrenal cortex. Rev Endocr Metab Disord 2:253-267
26. Morrison JL, Riggs KW, Chien C, Gruber N, Mcmilen IC, Rurak DW 2004 Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes. Pediatr Res 56:40-46
27. Gilmore DP 1988 Neurosecretion and neurotransmitters of the fetal hypothalamus. In: Polin RA, Fox WW (eds) Fetal and Neonatal Physiology. Philadelphia, PA: WB Saunders Company, pp 2395-2401
28. Fowden AL, Forhead AJ 2004 Endocrine mechanisms of intrauterine programming. Reproduction 127:515-526
29. van Beek JP, Guan H, Julan L, Yang K 2004 Glucocorticoids stimulate the expression of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human placental trophoblast cells. J Clin Endocrinol Metab 89:5614-5621
30. Ward AM, Syddall HE, Wood PJ, Chrousos GP, Phillips DI 2004 Fetal programming of the hypothalamic-pituitary-adrenal (HPA) axis: low birth weight and central HPA regulation. J Clin Endocrinol Metab 89:1227-1233
31. Finnegan LP 1990 Neonatal abstinence syndrome. In: Nelson NM (ed) Current Therapy in Neonatal-Perinatal Medicine-2. Toronto: B.C Decker, pp 314-320
32. Davidson S, Sokolover N, Erlich A, Litwin A, Linder N, Sirota L 2008 New and improved Israeli reference of birth weight, birth length, and head circumference by gestational age: a hospital-based study. Isr Med Assoc J 10:130-134 (IMAJ)
33. Morrison JL, Chien C, Riggs KW, Gruber N, Rurak D 2002 Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth. Pediatr Res 51:433-442
34. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM 2001 Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477-486
35. Warden SJ, Rohling AG, Sanders MS, Bliziotes MM, Turner CH 2005 Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146:685-693
36. Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, Stashenko P 2004 Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19:1420-1431
37. Raap DK, Vannde Kar LD 1999 Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 65:1217-1235
38. Strinic T, Roje D, Marusic J, Capkun V 2007 Cord blood cortisol level is lower in growth-restricted newborns. J Obstet Gynaecol Res 33:144-150
39. Seckl JR 2001 Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms. Mol Cell Endocrinol 185:61-71
40. Cianfarani S, Germani D, Rossi L, Argiro G, Boemi S, Lemon M, Holly JM, Branca F 1998 IGF-I and IGF-binding protein-1 are related to cortisol in human cord blood. Eur J Endocrinol 138:524-529
41. Oberlander TF, Grunau R, Mayes L, Riggs W, Rurak D, Papsdorf M, Misri S, Weinberg J 2008 Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 84:689-697
42. Perez-Neri I, Montes S, Ojeda-Lopez C, Ramirez-Bermudez J, Rios C 2008 Modulation of neurotransmitter systems by dehydroepiandrosterone and dehydroepiandrosterone sulfate: mechanisms of action and relevance to psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 32:1118-1130
43. Gitlin M, Altshuler LL, Frye MA, Suri R, Huynh EL, Fairbanks I, Bauer M, Korenman S 2004 Peripheral thyroid hormones and response to selective serotonin uptake inhibitors. J Psychiatry Neurosci 29:383-386